More $22 Drugs

摘要

On July 24, the DoD Beneficiary Advisory Panel (BAP) met to review DoD proposals to move some migraine and osteoporosis medications to the third tier, or $22 copayment level. Migraine medications Axert, Frova, and Amerge will be moved to the higher $22 copayment. Imitrex, Zomig, Maxalt, Relpax, and Treximet will continue to be available at their current copayment.